Despite declining transaction volume in 2024, life sciences companies are pursuing bigger acquisitions to secure drug portfolios, integrate AI capabilities, and navigate the looming patent cliff.
As AI reshapes the competitive landscape, technology companies are pursuing bigger acquisitions despite declining deal volume, with blockbuster transactions exceeding $30 billion becoming the new normal.
In this fictional scenario, a fast-growing beverage company’s dream acquisition turns into a nightmare when a cyber attack cripples its operations and exposes the devastating consequences of an untested business continuity plan.
Deal volume stabilizes around 750-800 transactions annually while private equity maintains dominance and buyer pool shrinks significantly, Optis Partners reports.
Charlie Tice is the Private Equity National Practice Lead for Travelers. Risk & Insurance recently spoke to him as part of our expanded coverage of our 2025 M&A Power Broker® winners and finalists.
M&A activity in the insurance industry stabilizes as a steady supply of sellers meets a diverse buyer landscape, according to to the latest Q3 2024 update from Optis Partners .
Insurance M&A activity declines to 16-quarter low, but is higher than a decade ago and private equity interest remains strong, according to OPTIS Partners analysis.